Sanofi India (BOM:500674) Other Current Payables: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500674 Sanofi India Ltd BOM:500674
82 GF Score
Price ₹3,246.40
GF Value ₹4,380.97
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Sanofi India Other Current Payables?

Sanofi India BOM:500674 -0.22% 82 Other Current Payables is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:500674 with a GF Score™ of 82/100 and a GF Value™ of ₹4,380.97 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Sanofi India's Other Current Payables for the quarter that ended in Jun. 2026 was ₹0 Mil.

Sanofi India's quarterly Other Current Payables declined from Dec. 2025 (₹566 Mil) to Mar. 2026 (₹0 Mil) but then stayed the same from Mar. 2026 (₹0 Mil) to Jun. 2026 (₹0 Mil).

Sanofi India's annual Other Current Payables increased from Dec. 2023 (₹125 Mil) to Dec. 2024 (₹616 Mil) but then declined from Dec. 2024 (₹616 Mil) to Dec. 2025 (₹566 Mil).

Sanofi India Other Current Payables Related Terms

Sanofi India Other Current Payables Historical Data

* Premium members only.

The historical data trend for Sanofi India's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi India Other Current Payables Chart

Sanofi India Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.00 85.00 125.00 616.00 566.00

Sanofi India Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 566.00 0.00 0.00
BOM:500674
82GF Score
Sanofi India Ltd BOM:500674
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi India Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ₹0 Mil mean?
Sanofi India (BOM:500674) has a Other Current Payables of ₹0 Mil as of Jun. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Sanofi India and its competitors.
Is Sanofi India's Other Current Payables too high?
Sanofi India's current Other Current Payables is ₹0 Mil. Overall, Sanofi India has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi India's Other Current Payables compare to LLY and JNJ?
Sanofi India's Other Current Payables of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Sanofi India and its competitors. Sanofi India's current Other Current Payables is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi India stock overvalued right now?
Based on GuruFocus' analysis, Sanofi India (BOM:500674) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹4,380.97, compared to a current price of ₹3,246.40 — trading 25.9% below its estimated fair value. The current Other Current Payables is ₹0 Mil. Sanofi India's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Sanofi India (BOM:500674), the current Other Current Payables is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi India (BOM:500674) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued. The current stock price of ₹3,246.40 is trading 25.9% below its estimated GF Value™ of ₹4,380.97. GuruFocus considers Sanofi India to be Modestly Undervalued.

Key valuation signals for BOM:500674:

  • Other Current Payables: ₹0 Mil
  • GF Value™: ₹4,380.97 vs. price of ₹3,246.40 (25.9% below fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the BOM:500674 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi India Business Description

Other Exchanges SANOFI:India
Address Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
82GF Score

Get the complete analysis for BOM:500674

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3,246.40
Price
₹4,380.97
GF Value